Press & News

People are different and so is their cancer, patients should be treated individually.

Meet us at Sedermeradagen in Göteborg

September 12, 2018

IR

Don’t miss the opportunity to attend Sedermerdadagen in Göteborg the 11th October 2018 from 11.00-18.00, where you will be able to meet interesting companies in the micro and small caps segment. 2cureX CEO, Ole Thastrup will participate and will talk about the latest news.

It is free to join.

Click here (https://www.sedermera.se/sv/evenemang/2018-10-11/sedermeradagen-goteborg-2018) and sign up to Sedermeradagen. We hope to see you.

Certified Adviser

Sedermera Fondkommission is the Certified Adviser of 2cureX. 

For more information about 2cureX:

Ole Thastrup, CEO;        

E-mail: ot@2cureX.com

Phone: +45 22 11 53 99;               

URL: www.2curex.com

About 2cureX

2cureX has developed a test called IndiTreat® (Individual Treatment Design), which is a patented method for selecting the right drug for the right patient. IndiTreat® establishes thousands of 3D micro-tumors that are functionally similar to the patient’s tumor. From a large panel of approved cancer treatments IndiTreat® selects the best treatment for the individual patient. IndiTreat® is expected to become a standard tool in the treatment design for cancer patients.

IndiTreat® is currently being clinically validated in colorectal and ovarian cancer.

The company is listed at the Nasdaq First North stock exchange in Stockholm (symbol “2CUREX”).